vs
GENESCO INC（GCO）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是GENESCO INC的1.0倍（$622.0M vs $616.2M），Royalty Pharma plc净利率更高（34.4% vs 0.9%，领先33.6%），Royalty Pharma plc同比增速更快（4.8% vs 3.3%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -8.7%）
Genesco Inc是总部位于美国田纳西州纳什维尔的上市企业，核心业务为品牌鞋履及配饰零售，同时开展品牌与授权鞋履的批发业务。该公司起源于1924年成立的贾曼鞋业公司，最初为鞋履制造商，1933年更名为通用鞋业，1939年完成上市，目前名称为原企业名的首字母缩写。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
GCO vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.0倍
$616.2M
营收增速更快
RPRX
高出1.4%
3.3%
净利率更高
RPRX
高出33.6%
0.9%
两年增速更快
RPRX
近两年复合增速
-8.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $616.2M | $622.0M |
| 净利润 | $5.4M | $214.2M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 1.4% | 62.4% |
| 净利率 | 0.9% | 34.4% |
| 营收同比 | 3.3% | 4.8% |
| 净利润同比 | 128.3% | 2.9% |
| 每股收益（稀释后） | $0.50 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GCORPRX
| Q4 25 | $616.2M | $622.0M | ||
| Q3 25 | $546.0M | $609.3M | ||
| Q2 25 | $474.0M | $578.7M | ||
| Q1 25 | $745.9M | $568.2M | ||
| Q4 24 | $596.3M | $593.6M | ||
| Q3 24 | $525.2M | $564.7M | ||
| Q2 24 | $457.6M | $537.3M | ||
| Q1 24 | $739.0M | $568.0M |
净利润GCORPRX
| Q4 25 | $5.4M | $214.2M | ||
| Q3 25 | $-18.5M | $288.2M | ||
| Q2 25 | $-21.2M | $30.2M | ||
| Q1 25 | $34.4M | $238.3M | ||
| Q4 24 | $-18.9M | $208.2M | ||
| Q3 24 | $-10.0M | $544.0M | ||
| Q2 24 | $-24.3M | $102.0M | ||
| Q1 24 | $27.2M | $4.8M |
毛利率GCORPRX
| Q4 25 | 46.8% | — | ||
| Q3 25 | 45.8% | — | ||
| Q2 25 | 46.7% | — | ||
| Q1 25 | 46.9% | — | ||
| Q4 24 | 47.8% | — | ||
| Q3 24 | 46.8% | — | ||
| Q2 24 | 47.3% | — | ||
| Q1 24 | 46.3% | — |
营业利润率GCORPRX
| Q4 25 | 1.4% | 62.4% | ||
| Q3 25 | -2.6% | 70.1% | ||
| Q2 25 | -5.9% | 36.3% | ||
| Q1 25 | 6.2% | 94.0% | ||
| Q4 24 | 1.7% | 60.9% | ||
| Q3 24 | -2.0% | — | ||
| Q2 24 | -7.0% | 50.2% | ||
| Q1 24 | 5.0% | -13.0% |
净利率GCORPRX
| Q4 25 | 0.9% | 34.4% | ||
| Q3 25 | -3.4% | 47.3% | ||
| Q2 25 | -4.5% | 5.2% | ||
| Q1 25 | 4.6% | 41.9% | ||
| Q4 24 | -3.2% | 35.1% | ||
| Q3 24 | -1.9% | 96.3% | ||
| Q2 24 | -5.3% | 19.0% | ||
| Q1 24 | 3.7% | 0.8% |
每股收益（稀释后）GCORPRX
| Q4 25 | $0.50 | $0.49 | ||
| Q3 25 | $-1.79 | $0.67 | ||
| Q2 25 | $-2.02 | $0.07 | ||
| Q1 25 | $3.16 | $0.55 | ||
| Q4 24 | $-1.76 | $0.46 | ||
| Q3 24 | $-0.91 | $1.21 | ||
| Q2 24 | $-2.23 | $0.23 | ||
| Q1 24 | $2.29 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.0M | $618.7M |
| 总债务越低越好 | $89.5M | $9.0B |
| 股东权益账面价值 | $513.8M | $9.7B |
| 总资产 | $1.5B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.17× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资GCORPRX
| Q4 25 | $27.0M | $618.7M | ||
| Q3 25 | $41.0M | $938.9M | ||
| Q2 25 | $21.7M | $631.9M | ||
| Q1 25 | $34.0M | $1.1B | ||
| Q4 24 | $33.6M | $929.0M | ||
| Q3 24 | $45.9M | $950.1M | ||
| Q2 24 | $19.2M | $1.8B | ||
| Q1 24 | $35.2M | $843.0M |
总债务GCORPRX
| Q4 25 | $89.5M | $9.0B | ||
| Q3 25 | $71.0M | $8.9B | ||
| Q2 25 | $121.0M | $8.0B | ||
| Q1 25 | $0 | $7.6B | ||
| Q4 24 | $100.1M | $7.6B | ||
| Q3 24 | $77.8M | $7.6B | ||
| Q2 24 | $59.4M | $7.6B | ||
| Q1 24 | $34.7M | $6.1B |
股东权益GCORPRX
| Q4 25 | $513.8M | $9.7B | ||
| Q3 25 | $506.4M | $9.6B | ||
| Q2 25 | $522.2M | $9.5B | ||
| Q1 25 | $547.0M | $9.8B | ||
| Q4 24 | $516.9M | $10.3B | ||
| Q3 24 | $532.6M | $10.3B | ||
| Q2 24 | $548.5M | $9.8B | ||
| Q1 24 | $571.2M | $9.9B |
总资产GCORPRX
| Q4 25 | $1.5B | $19.6B | ||
| Q3 25 | $1.4B | $19.3B | ||
| Q2 25 | $1.4B | $18.3B | ||
| Q1 25 | $1.3B | $17.6B | ||
| Q4 24 | $1.4B | $18.2B | ||
| Q3 24 | $1.4B | $18.0B | ||
| Q2 24 | $1.3B | $17.7B | ||
| Q1 24 | $1.3B | $16.1B |
负债/权益比GCORPRX
| Q4 25 | 0.17× | 0.92× | ||
| Q3 25 | 0.14× | 0.93× | ||
| Q2 25 | 0.23× | 0.84× | ||
| Q1 25 | 0.00× | 0.78× | ||
| Q4 24 | 0.19× | 0.74× | ||
| Q3 24 | 0.15× | 0.74× | ||
| Q2 24 | 0.11× | 0.78× | ||
| Q1 24 | 0.06× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-12.9M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-31.5M | — |
| 自由现金流率自由现金流/营收 | -5.1% | — |
| 资本支出强度资本支出/营收 | 3.0% | — |
| 现金转化率经营现金流/净利润 | -2.41× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $23.5M | — |
8季度趋势，按日历期对齐
经营现金流GCORPRX
| Q4 25 | $-12.9M | $827.1M | ||
| Q3 25 | $86.3M | $702.6M | ||
| Q2 25 | $-101.0M | $364.0M | ||
| Q1 25 | $117.0M | $596.1M | ||
| Q4 24 | $-23.1M | $742.5M | ||
| Q3 24 | $27.7M | $703.6M | ||
| Q2 24 | $-33.7M | $658.2M | ||
| Q1 24 | $118.3M | $664.6M |
自由现金流GCORPRX
| Q4 25 | $-31.5M | — | ||
| Q3 25 | $71.7M | — | ||
| Q2 25 | $-119.9M | — | ||
| Q1 25 | $103.3M | — | ||
| Q4 24 | $-36.2M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $-40.1M | — | ||
| Q1 24 | $107.8M | — |
自由现金流率GCORPRX
| Q4 25 | -5.1% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | -25.3% | — | ||
| Q1 25 | 13.8% | — | ||
| Q4 24 | -6.1% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | -8.8% | — | ||
| Q1 24 | 14.6% | — |
资本支出强度GCORPRX
| Q4 25 | 3.0% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 1.4% | — |
现金转化率GCORPRX
| Q4 25 | -2.41× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | 3.40× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 4.35× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GCO
| Journeys Group Segment | $376.7M | 61% |
| Schuh Group Segment | $123.8M | 20% |
| Johnston And Murphy Group Segment | $81.2M | 13% |
| Genesco Brands Segment | $34.6M | 6% |
| Store Restructuring | $3.9M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
